KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Liabilities from Discontinued Operations (2022)

Historic Liabilities from Discontinued Operations for Travere Therapeutics (TVTX) over the last 1 years, with Q4 2022 value amounting to $64.2 million.

  • Travere Therapeutics' Liabilities from Discontinued Operations changed N/A to $64.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was $64.2 million, marking a year-over-year change of. This contributed to the annual value of $64.2 million for FY2022, which is N/A changed from last year.
  • Per Travere Therapeutics' latest filing, its Liabilities from Discontinued Operations stood at $64.2 million for Q4 2022.
  • Travere Therapeutics' 5-year Liabilities from Discontinued Operations high stood at $64.2 million for Q4 2022, and its period low was $64.2 million during Q4 2022.